1-3 of 3
David Newell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival

Free
Liam Cornell, Joanne M. Munck, Clara Alsinet, Augusto Villanueva, Laura Ogle, Catherine E. Willoughby, Despina Televantou, Huw D. Thomas, Jennifer Jackson, Alastair D. Burt, David Newell, John Rose, Derek M. Manas, Geoffrey I. Shapiro, Nicola J. Curtin, Helen L. Reeves
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 925–933.
https://doi.org/10.1158/1078-0432.CCR-14-0842
Published: 16 February 2015
View articletitled, DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Open the PDF for DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival in another window
Includes: Supplementary data
Journal Articles

CR-UK biomarker roadmaps

Free
Maria Lioumi, David Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): B33.
https://doi.org/10.1158/DIAG-10-B33
Published: 15 August 2014
View articletitled, CR-UK biomarker roadmaps
Journal Articles

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Free
Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell, Adrian Harris, Patrick Johnson, Heidi Steinfeldt, Raz Dewji, Diane Wang, Lesley Robson, Hilary Calvert
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7917–7923.
https://doi.org/10.1158/1078-0432.CCR-08-1223
Published: 01 December 2008
View articletitled, Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors in another window